Diaceutics Reports Strong Revenue Growth and Confirms Full-Year Outlook


Diaceutics, the U.K. diagnostics company, has announced a significant increase in first-half revenue, reaffirming its full-year outlook due to strong order book growth. The company’s success is driven by the improved visibility provided by this growth.

Revenue Growth

  • Diaceutics reported a 32% rise in revenue, amounting to £9.9 million ($12.7 million).
  • On a constant currency basis, the revenue increase was 25%.
  • Notably, 47% of the revenue in this period was recurring, representing an improvement from the previous year’s 37%.

Order Book Expansion

  • The order book expanded by 43%, reaching approximately £24.1 million as of June 30.
  • Of this sum, around £6.3 million is expected to be realized in the second half of the year.

Positive Validation and Outlook

  • Diaceutics attributes its success and momentum during this period to the validation of its strategy.
  • The company’s performance aligns with management expectations, although specific figures were not disclosed.
  • Diaceutics expressed confidence in its ability to continue accelerating its growth strategy and capitalize on the market opportunity.
  • They aim to become the primary commercialization partner for pharma and biotech companies launching precision medicines.

As a result of this positive announcement, shares of Diaceutics rose by 4.0 pence or 4.6% to reach 91.5 pence at 0814 GMT.

Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

China’s Property Sector Receives Government Support

Next Post

Inpixon and XTI Aircraft Agree to Merge

Related Posts